Topics

Biosimilar Switching Studies May Not Be Worth Effort For US Interchangeability, Sponsors Say

17:24 EST 7 Nov 2019 | SCRIP

Payers are driving the selection of reference products or biosimilars, creating an ‘artificial interchangeability’ unlikely to be affected by the...

      

Related Stories

 

Original Article: Biosimilar Switching Studies May Not Be Worth Effort For US Interchangeability, Sponsors Say

NEXT ARTICLE

More From BioPortfolio on "Biosimilar Switching Studies May Not Be Worth Effort For US Interchangeability, Sponsors Say"

Quick Search

Relevant Topic

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...